Welcome to the BCCJ: Innovacell K.K.

The BCCJ proudly welcomes Innovacell K.K. to the Chamber

Innovacell is a biotechnology company focused on developing, manufacturing and marketing cell therapies for the treatment of incontinence-related indications.  The company was originally established in 2000 as a spin-off from the Medical University of Innsbruck (Austria) and, utilizing a triangular merger, converted into a Japanese biotech (with a wholly-owned Austrian subsidiary called Innovacell AG) in late February 2021.

The company owns and operates one of the longest standing GMP manufacturing facilities for cellular therapies in Europe and currently has regulatory approval to manufacture cell therapy investigational products for clinical trials across various cell types; autologous skeletal muscle cells, skin fibroblasts, and hair follicle cells.

Innovacell currently has three products in its pipeline two of which are already in late-stage clinical development.  In the coming months they will look to commence a multi-regional Phase III clinical trial across Japan and 10 other countries in Europe for their lead product, ICEF15; the successful completion of which will allow Innovacell an opportunity to be the world’s first non-oncology related cellular therapy biotech to have a product approved in two major pharmaceutical jurisdictions.

Furthermore, Innovacell is looking to IPO on the Tokyo Stock Exchange and is currently conducting a capital raise with the aim of securing further funding in order to further clinical development of their investigational products and fund the envisioned IPO.

For more information please visit Innovacell’s subsidiary’s website

CONTACT
Colin Lee Novick | Director
[email protected]